The latest price target for Oncology Institute (NASDAQ:TOI) was reported by Jefferies on February 26, 2024. The analyst firm set a price target for $2.50 expecting TOI to rise to within 12 months (a possible 1136.40% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Oncology Institute (NASDAQ:TOI) was provided by Jefferies, and Oncology Institute their buy rating.

There is no last upgrade for Oncology Institute

There is no last downgrade for Oncology Institute.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oncology Institute, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oncology Institute was filed on February 26, 2024 so you should expect the next rating to be made available sometime around February 26, 2025.

While ratings are subjective and will change, the latest Oncology Institute (TOI) rating was a with a price target of $0.00 to $2.50. The current price Oncology Institute (TOI) is trading at is $0.20, which is within the analyst’s predicted range.